# US 2019/0167691 A1 · Transient protection of hematopoietic stem and progenitor cells against ionizing radiation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167691 A1
- Document ID: US20190167691A1
- Status: Published application
- Kind: A1
- Application number: 16/268,317
- Filed: 2019-02-05
- Published: 2019-06-06
- Earliest claimed: 2013-03-15
- Assignees: G1 Therapeutics, Inc.
- Applicants: G1 Therapeutics, Inc.
- Inventors: Jay Copeland Strum; John Emerson Bisi; Patrick Joseph Roberts; Francis Xavier Tavares
- Web page: https://patentgrep.com/patent/US20190167691A1

## CPC

- A61K 31/527: spiro-condensed
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/196: {Thrombopoietin}
- A61K 38/208: {IL-12}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- C07D 487/20: Spiro-condensed systems
- A61N 2005/1094: {Shielding, protecting against radiation}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.

## Claims

### Claim 1

A method of reducing ionizing radiation induced apoptosis in hematopoietic stem cells and/or progenitor cells (HSPCs) in a human exposed to ionizing radiation, the method comprising administering to the human an effective amount of a CDK4/6 inhibitor compound having the structure:
or its pharmaceutically acceptable salt, wherein the CDK4/6 inhibitor compound is administered up to about 24 hours after exposure to the ionizing radiation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the CDK4/6 inhibitor compound is administered up to about 12 hours after exposure to the ionizing radiation.

### Claim 3

A method for reducing the effect of ionizing radiation exposure on cyclin-dependent kinase 4 (CDK4) replication-dependent hematopoietic stem cells and/or progenitor cells (HSPCs) in a human receiving ionizing radiation for the treatment of a CDK4/6 replication independent cellular proliferation disorder, the method comprising administering to the human an effective amount of a CDK4/6 inhibitor compound having the structure:
or its pharmaceutically acceptable salt;
wherein the CDK4/6 inhibitor is administered less than about 4 hours prior to receiving ionizing radiation.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cellular proliferation disorder is a CDK4/6 replication independent cancer.

### Claim 5 (depends on 3)

The method of claim 3, wherein administration of the CDK4/6 inhibitor compound does not affect growth of diseased cells.

### Claim 6 (depends on 3)

The method of claim 3, wherein the human is further treated with hematopoietic growth factors upon dissipation of the CDK4/6 inhibitor's inhibitory effect.

### Claim 7 (depends on 6)

The method of claim 6, wherein the hematopoietic growth factor is selected form the group consisting of granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), thrombopoietin, interleukin (IL)-12, steel factor, and erythropoietin (EPO).

### Claim 8

A method of reducing ionizing radiation induced apoptosis in cyclin-dependent kinase 4 (CDK4) replication-dependent hematopoietic stem cells and/or progenitor cells (HSPCs) in a human exposed to ionizing radiation, the method comprising administering to the human an effective amount of a CDK4/6 inhibitor compound having the structure:
or its pharmaceutically acceptable salt, wherein the CDK4/6 inhibitor compound is administered up to about 24 hours after exposure to the ionizing radiation.

### Claim 9 (depends on 8)

The method of claim 8, wherein the CDK4/6 inhibitor compound is administered up to about 12 hours after exposure to the ionizing radiation.

### Claim 10

A method for reducing the effect of ionizing radiation exposure on cyclin-dependent kinase 4 (CDK4) replication-dependent hematopoietic stem cells and/or progenitor cells (HSPCs) in a human receiving ionizing radiation for the treatment of a CDK4/6 replication independent cellular proliferation disorder, the method comprising administering to the human an effective amount of a CDK4/6 inhibitor compound having the structure:
or its pharmaceutically acceptable salt;
wherein the CDK4/6 inhibitor is administered less than about 4 hours prior to receiving ionizing radiation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cellular proliferation disorder is a CDK4/6 replication independent cancer.

### Claim 12 (depends on 10)

The method of claim 10, wherein administration of the CDK4/6 inhibitor compound does not affect growth of diseased cells.

### Claim 13 (depends on 10)

The method of claim 10, wherein the human is further treated with hematopoietic growth factors upon dissipation of the CDK4/6 inhibitor's inhibitory effect.

### Claim 14 (depends on 13)

The method of claim 13, wherein the hematopoietic growth factor is selected form the group consisting of granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), thrombopoietin, interleukin (IL)-12, steel factor, and erythropoietin (EPO).
